anlotinib + TQB2450 + oxaliplatin + S-1

This is a **four-drug combination regimen** consisting of anlotinib, TQB2450, oxaliplatin, and S-1: - **Anlotinib** is a small molecule, oral, multi-target tyrosine kinase inhibitor with antiangiogenic and antitumor activity, notably inhibiting VEGFR, FGFR, PDGFR, and c-Kit, and is primarily developed for advanced solid tumors including lung, soft tissue sarcoma, and others[1][2][4]. - **TQB2450** (benmelstobart) is a humanized monoclonal antibody targeting programmed death-ligand 1 (**PD-L1**), functioning as a checkpoint inhibitor to enhance immune response against tumors[2][5][8]. - **Oxaliplatin** is a platinum-based cytotoxic chemotherapeutic, causing DNA cross-linking and cell death; it is a cornerstone in the treatment of gastrointestinal malignancies, notably colorectal and gastric cancers[3][6][9]. - **S-1** is an oral combination of tegafur (a prodrug of fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (an orotate phosphoribosyltransferase inhibitor), designed to enhance the efficacy of fluoropyrimidine chemotherapy while reducing gastrointestinal toxicity; it is approved for gastric, lung, and colorectal cancers in Asia[1][3][6][9]. This combination aims to leverage antiangiogenic and immune checkpoint blockade, together with cytotoxic chemotherapy, for synergistic antitumor efficacy, and is being explored in clinical trials for a variety of advanced solid tumors, including (but likely not limited to) biliary tract cancers, non-small cell lung cancer, esophageal squamous cell carcinoma, and gastrointestinal cancers[2][5][8].

Brand names

S-1 (brand name for the tegafur/gimeracil/oteracil combination)

Other names

SOX (for the oxaliplatin + S-1 doublet)benmelstobart (for TQB2450, though sometimes listed under code, not brand)TQB2450 (no further brand name known as of now)